Skip to main content
Premium Trial:

Request an Annual Quote

Olink Prices $85M Public Offering

NEW YORK – Swedish proteomics company Olink announced Wednesday that it has priced a public offering of 5,831,028 American Depositary Shares (ADS), each representing one common share in the company, at $20 per share.

The offering consists of 4,250,000 ADSs offered by Olink and 1,581,028 ADSs offered by certain shareholders of the company. Olink will gross approximately $85 million from the offering. It will not receive any proceeds from the latter category of shares.

Additionally, Olink has granted the underwriters a 30-day option to purchase an additional 874,654 shares from the company.

Goldman Sachs Bank Europe SE and J.P. Morgan Securities are acting as lead bookrunning managers for the offering. SVB Securities and Canaccord Genuity are acting as joint bookrunning managers for the offering.

A shelf registration statement relating to these securities was declared automatically effective by the Securities and Exchange Commission on Jan. 18.

In Thursday morning trading on Nasdaq, Olink shares were down 17 percent to $19.95.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.